(Q38250719)

1 September 2017

1 reference

title

Antihyperglycaemic therapies and cancer risk (English)

1 reference

1 September 2017

4

Hans-Ulrich Häring

1 reference

1 September 2017

2

Harald Staiger

1 reference

1 September 2017

3

Andreas Fritsche

1 reference

1 September 2017

Stefan Z Lutz

1

1 reference

1 September 2017

language of work or name

English

0 references

publication date

17 September 2014

1 reference

Diabetes and Vascular Disease Research

1 September 2017

published in

1 reference

1 September 2017

volume

11

1 reference

1 September 2017

issue

6

1 reference

1 September 2017

page(s)

371-389

1 reference

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Associations of hyperglycemia and insulin usage with the risk of cancer in type 2 diabetes: the Hong Kong diabetes registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Diabetes mellitus, fasting glucose, and risk of cause-specific death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Substantially increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis of epidemiologic evidence in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Diabetes and breast cancer risk: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The role of preexisting diabetes mellitus on incidence and mortality of endometrial cancer: a meta-analysis of prospective cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Pre-existing diabetes mellitus increases the risk of gastric cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Physical activity, diabetes, and risk of thyroid cancer: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metabolic effects of metformin in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin Improves Insulin Signaling in Obese Rats via Reduced IKKβAction in a Fiber-Type Specific Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Current strategies for the inhibition of hepatic glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Mechanism by which metformin reduces glucose production in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin Inhibits Hepatic Gluconeogenesis Through AMP-Activated Protein Kinase-Dependent Regulation of the Orphan Nuclear Receptor SHP

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Investigating metformin for cancer prevention and treatment: the end of the beginning

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and cancer occurrence in insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical t

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Antidiabetic therapies affect risk of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Anti-tumour activity of CS-7017, a selective peroxisome proliferator-activated receptor gamma agonist of thiazolidinedione class, in human tumour xenografts and a syngeneic tumour implant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The high affinity peroxisome proliferator-activated receptor-gamma agonist RS5444 inhibits both initiation and progression of colon tumors in azoxymethane-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

PPARgamma inhibits the expression of c-MET in human gastric cancer cells through the suppression of Ets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Novel high-affinity PPARgamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Cancer risk for patients using thiazolidinediones for type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Promotion of colon tumors in C57BL/6J-APC(min)/+ mice by thiazolidinedione PPARgamma agonists and a structurally unrelated PPARgamma agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Peroxisome proliferator-activated receptor gamma agonist troglitazone induces colon tumors in normal C57BL/6J mice and enhances colonic carcinogenesis in Apc1638 N/+ Mlh1+/- double mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Dose effect of thiazolidinedione on cancer risk in type 2 diabetes mellitus patients: a six-year population-based cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Cancer risks in thiazolidinedione users compared to other anti-diabetic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

p53 is not inactivated in B6C3F1 mouse vascular tumors arising spontaneously or associated with long-term administration of the thiazolidinedione troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Rodent carcinogenicity with the thiazolidinedione antidiabetic agent troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Carcinogenic susceptibility of rasH2 mice to troglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

A phase 1 study of efatutazone, an oral peroxisome proliferator-activated receptor gamma agonist, administered to patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Association between cancer prevalence and use of thiazolidinediones: results from the Vermont Diabetes Information System

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

ATP-sensitive potassium channelopathies: focus on insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Insulin and insulin-like growth factor signalling in neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Effects of sulfonylureas on tumor growth: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The biology of incretin hormones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The natural history of hereditary pancreatitis: a national series

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Exenatide (exendin-4)-induced pancreatitis: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Exenatide-induced acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Acute pancreatitis associated with liraglutide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Incretin-based therapies in the treatment of type 2 diabetes--more than meets the eye?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

GLP-1-based therapies: the dilemma of uncertainty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The efficacy and safety of liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Effects of glucagon and glucagon-like peptide-1-(7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Secretion of calcitonin from the thyroid gland increases in aged rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

C-Cell Hyperplasia Preceding Medullary Thyroid Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

A cohort study of acute pancreatitis in relation to exenatide use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Dipeptidyl peptidase IV (DPPIV) inhibits cellular invasion of melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Dipeptidyl peptidase IV (DPPIV), a candidate tumor suppressor gene in melanomas is silenced by promoter methylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

CD26/dipeptidyl peptidase IV regulates prostate cancer metastasis by degrading SDF-1/CXCL12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Dipeptidyl peptidase IV expression in endometrial endometrioid adenocarcinoma and its inverse correlation with tumor grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Involvement of DPPIV/CD26 in epithelial morphology and suppressed invasive ability in ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Beneficial endocrine but adverse exocrine effects of sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes: interactions with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

A case of severe acute necrotizing pancreatitis after administration of sitagliptin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Functional insulin receptors are overexpressed in thyroid tumors: is this an early event in thyroid tumorigenesis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Elevated insulin receptor content in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Insulin receptor isoforms A and B as well as insulin receptor substrates-1 and -2 are differentially expressed in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Proliferative effect of Apidra (insulin glulisine), a rapid-acting insulin analogue on mammary epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Mitogenic action of insulin: friend, foe or 'frenemy'?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Combined randomised controlled trial experience of malignancies in studies using insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Insulin glargine and cancer risk in patients with diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Insulin glargine and risk of cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Diabetes treatment with insulin glargine and risk of malignancy: methodological pitfalls and ethical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Doses of insulin and its analogues and cancer occurrence in insulin-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Insulin use and cancer risk in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in APC gene 1309 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Diabetes and risk of subsequent gastric cancer: a population-based cohort study in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Increased risk of gastrointestinal malignancy in patients with diabetes mellitus and correlations with anti-diabetes drugs: a nationwide population-based study in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Thyroid cancer risk is not increased in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

Basal Insulin and Cardiovascular and Other Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1479164114549553

21 January 2018

Identifiers

DOI

10.1177/1479164114549553

1 reference

1 September 2017

1 reference